Tuesday May 03, 2022

Joyce O’Shaughnessy MD | Pembrolizumab + KEYNOTE-522 Trial, Trastuzumab Deruxtecan, CDK 4/6 Inhibitors & MonarchE Trial Data

On this episode, PrecisCa speaks with Dr. Joyce O'Shaughnessy, a medical oncologist and the Director of Breast Cancer Research Program at Baylor University Medical Center in Dallas, Texas. 
 
Dr. O'Shaughnessy sits down with us to answer the following questions:
  • Which breast cancer patients are eligible for preoperative pembrolizumab in the curative setting based on the KEYNOTE-522 trial? What about adjuvant pembrolizumab?
  • How is trastuzumab deruxtecan optimally utilized for HER2+ metastatic breast cancer?
  • Which CDK 4/6 inhibitor is recommended for treatment of HR+ HER2- metastatic breast cancer based on available survival data?
  • Can you discuss the data from the MonarchE Trial that led to FDA approval of abemaciclib in October 2021?
Joyce A. O’Shaughnessy, M.D. focuses on breast cancer prevention and treatment. She is Co-Chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center and for The US Oncology Network and is a member of the Scientific Advisory Board for US Oncology Research Network. In 2009 D Magazine elected Dr. O’Shaughnessy as one of the best hematology oncologists in Dallas, Texas. 
 

Dr. O’Shaughnessy received her M.D. from Yale University Medical School. Her internship and residency in internal medicine were completed at Massachusetts General Hospital in 1985. She concluded a fellowship in medical oncology at the National Cancer Institute in 1987 and was a Senior Investigator there until 1995. Dr. O’Shaughnessy is a member of American Association for Cancer Research; American Society of Clinical Oncology; American Medical Women’s Association; American Medical Association; American College of Physicians; and Women in Cancer Research. Dr. O’Shaughnessy is an Associate Editor, Clinical Breast Cancer Journal; founder, The School of Breast Oncology.

Visit www.precisca.com for more resources, content, and access to our entire catalogue of educational content. 

2022 All rights reserved.

Version: 20230822